Advanced Non-Small Cell Lung Carcinoma (DBCOND0071627)

Identifiers

Synonyms

Stage IV Non-small Cell Lung Cancer (NSCLC) / Stage IV Non-Small Cell Lung Cancer / Stage 4 Non-small cell lung cancer

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT05967533	The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors	No drug interventions	treatment	1	recruiting
NCT05198154	ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC	No drug interventions	Not Available	Not Available	recruiting
NCT04186988	[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy	No drug interventions	diagnostic	0	withdrawn
NCT04754815	Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC	Paclitaxel Pembrolizumab Pemetrexed	treatment	2	withdrawn
NCT04762199	MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer	Osimertinib	treatment	1	recruiting
NCT03191149	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Osimertinib	treatment	2	recruiting
NCT05166616	Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer	Minnelide Osimertinib Triptolide	treatment	1	recruiting
NCT04396535	Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer	Bintrafusp alfa Docetaxel	treatment	2	terminated
NCT05096663	Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)	Dexamethasone Docetaxel Gemcitabine Lexatumumab Nogapendekin alfa Pembrolizumab Pemetrexed Ramucirumab	treatment	2 / 3	active_not_recruiting
NCT03430063	A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer	Cemiplimab Ipilimumab	treatment	2	terminated
NCT05339022	Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial	No drug interventions	supportive_care	Not Available	recruiting
NCT06249282	Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer	Carfilzomib Sotorasib	treatment	1	recruiting
NCT04856176	A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy	Carboplatin Paclitaxel Pembrolizumab Pemetrexed	treatment	2	recruiting
NCT04902040	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin	treatment	1 / 2	recruiting
NCT05778708	Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients	No drug interventions	supportive_care	Not Available	recruiting
NCT05407038	Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue	No drug interventions	supportive_care	Not Available	active_not_recruiting
NCT02983578	Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer	Danvatirsen Durvalumab	treatment	2	active_not_recruiting
NCT03831932	Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer	Osimertinib Telaglenastat	treatment	1 / 2	active_not_recruiting
NCT04491942	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	Chloride ion Cisplatin Elimusertib Gemcitabine Platinum	treatment	1	active_not_recruiting
NCT02325349	PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents	Flotegatide (18F)	diagnostic	2	terminated
NCT02171286	The Oncopanel Pilot (TOP) Study	No drug interventions	Not Available	Not Available	completed
NCT05334329	Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors	Atezolizumab Cyclophosphamide Fludarabine	treatment	1	active_not_recruiting
NCT05498389	EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer	EMB-01 Osimertinib	treatment	1 / 2	not_yet_recruiting
NCT06096844	Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	Albumin human Carboplatin Paclitaxel Pembrolizumab Pemetrexed	treatment	3	recruiting